Daily OCS dose reduction

Secondary endpoint: Significantly more patients receiving NUCALA achieved a lower daily steroid dose during the last 4 weeks of treatment (OR: 0.20, 95% CI: 0.09, 0.41).1*

Based on this secondary endpoint2

59% of patients stat
Down arrow

59%

of patients

reduced steroid use to
≤7.5 mg in the last 4 weeks of
treatment vs 33% placebo

NUCALA 300 mg + SOC (n=40/68)
Placebo + SOC (n=23/68)

Results are descriptive.

Based on this secondary endpoint1,2

44% of patients stat
Down arrow

44%

of patients

reduced steroid use to
≤4.0 mg in the last 4 weeks of
treatment vs 7% placebo

NUCALA 300 mg + SOC (n=30/68)
Placebo + SOC (n=5/68)

Results are descriptive.

Based on this secondary endpoint1,2

18% of patients stat
Down arrow

18%

of patients

completely eliminated
daily OCS in the last 4 weeks of
treatment vs 3% placebo

NUCALA 300 mg + SOC (n=12/68)
Placebo + SOC (n=2/68)

Results are descriptive.

NUCALA and placebo were administered in addition to standard of care (SOC). After Week 4, OCS (prednisolone or prednisone) dose could be tapered, per physician judgment or a suggested protocol.

Other endpoint: Change in OCS dose over 52 weeks1

Median OCS dose over time2,3

Graph displaying change in OCS dose over time
Graph displaying change in OCS dose over time

These results are descriptive and not adjusted for multiplicity.

CI=confidence interval; OCS=oral corticosteroid; OR=odds ratio; SOC=standard of care.